FDA Approved: SAMSCA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

FDA supplemental application for SAMSCA (tolvaptan) from Otsuka America Pharmaceutical seeks labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia
• Syndrome of Inappropriate Antidiuretic Hormone Secretion

Drugs mentioned

• Samsca (tolvaptan)

Snippet

SUPPL AP for SAMSCA (TOLVAPTAN)